CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 57 enrolled
Drug / intervention
brentuximab vedotindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01393717
NCT01393717Phase 2Completed
CompareCT.gov

A Phase II Study of Brentuximab Vedotin as Salvage Therapy for Hodgkin Lymphoma Prior to Autologous Hematopoietic Stem Cell Transplantation

City of Hope Medical Center·interventional·Posted Jul 13, 2011·Updated Apr 26, 2018

In Brief

A Phase 2 clinical trial evaluating brentuximab vedotin for Recurrent Hodgkin Lymphoma and Refractory Hodgkin Lymphoma. Completed, enrolled 57 participants across 2 sites.

Detailed Summary

This phase II trial studies how well brentuximab vedotin before autologous (taken from an individual's own cells) stem cell transplant works in treating patients with Hodgkin lymphoma. Monoclonal antibody-drug conjugates, such as brentuximab vedotin, can block cancer growth in different ways by targeting certain cells.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 13, 2011
Enrollment StartOct 20, 2011
Primary CompletionFeb 1, 2017
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 15.0 years ago

Interventions

brentuximab vedotindrug

Given IV